TY - JOUR
T1 - Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis
T2 - A multi-institutional study in Japan
AU - Kubota, Tomohiro
AU - Takei, Syuji
AU - Shimizu, Masaki
AU - Yasumura, Junko
AU - Nakagishi, Yasuo
AU - Kizawa, Toshitaka
AU - Yashiro, Masato
AU - Wakiguchi, Hiroyuki
AU - Yamasaki, Yuichi
AU - Kawano, Yoshifumi
N1 - Publisher Copyright:
© 2017, © 2017 Japan College of Rheumatology.
PY - 2018/9/3
Y1 - 2018/9/3
N2 - Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p =.219], ESR [1.00 (0.78–1.30), p =.998], and DAS28-ESR [13.9 (2.08–409.82), p =.035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.
AB - Objective: To estimate target of treatment for long-term efficacy of the first biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). Methods: A retrospective cohort of patients with pJIA treated at six medical institutions in Japan between 1 March 2005 and 31 October 2014 was identified. The patients were divided by 2-year treatment periods with the first biologic agent into continuous treatment group and switching group. Three markers were examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate (ESR), and disease activity score (DAS) 28-ESR. Results: Thirty-two pJIA patients (8 boys, 24 girls) from 43 recruited patients were included in this study. The treatment periods with the first biologic agent in continuous treatment group (24 patients, 75%) was 40 months (median, range 24–119) and switching group (8 patients; 25%) was 9.5 months (median, 6–18). Markers [odds ratio (95% confidence interval)] at 3 months were MMP-3 [1.02 (0.99–1.05), p =.219], ESR [1.00 (0.78–1.30), p =.998], and DAS28-ESR [13.9 (2.08–409.82), p =.035]. The cut-off point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 (sensitivity, 87.5%; specificity, 87.5%). Conclusion: DAS28-ESR of 2.49 at 3 months after initiating the first biologic agent can be a target of sustained treatment in pJIA patients.
KW - Biologic agents
KW - DAS28-ESR
KW - juvenile idiopathic arthritis
KW - polyarticular type
KW - treat to target
UR - http://www.scopus.com/inward/record.url?scp=85039865192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039865192&partnerID=8YFLogxK
U2 - 10.1080/14397595.2017.1415628
DO - 10.1080/14397595.2017.1415628
M3 - Article
C2 - 29293033
AN - SCOPUS:85039865192
VL - 28
SP - 826
EP - 831
JO - Japanese Journal of Rheumatology
JF - Japanese Journal of Rheumatology
SN - 1439-7595
IS - 5
ER -